1. Aberrant expression of fibroblast growth factor receptor‐1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors
- Author
-
M. Suzanne Maliner, Raymond B. Nagle, Russell D. Klein, George T. Bowden, and Thirupandiyur S. Udayakumar
- Subjects
Cancer Research ,medicine.medical_specialty ,animal structures ,Fibroblast growth factor receptor 1 ,Biology ,medicine.disease ,medicine.disease_cause ,Metastasis ,Prostate cancer ,medicine.anatomical_structure ,Endocrinology ,Oncology ,Growth factor receptor ,Prostate ,Internal medicine ,embryonic structures ,LNCaP ,medicine ,Cancer research ,Matrilysin ,Carcinogenesis - Abstract
Matrix metalloproteinases (MMPs) degrade extracellular matrix proteins, and there is evidence that they play a role in tumor cell growth, invasion and metastasis. Matrilysin (MMP-7) is over-expressed in prostate cancer cells and increases prostate cancer cell invasion. Prostate stromal fibroblasts secrete a factor(s), including fibroblast growth factor-1 (FGF-1), which induces promatrilysin expression in the prostate carcinoma cell line LNCaP but not in normal prostate epithelial cells (PrECs). Since FGF-1 is present in the prostate, an altered sensitivity to FGF-1 might explain the up-regulation of matrilysin expression in prostate cancer cells compared to normal prostate epithelium. FGF receptor-1 (FGFR-1) is not normally expressed by normal prostate epithelial cells; however, aberrant expression of this receptor has been reported in prostate cancer cells, including the LNCaP cell line. We hypothesized that aberrant expression of FGFR-1 in PrECs would render them sensitive to induction of promatrilysin expression by recombinant FGF-1. To test this hypothesis, we transiently transfected PrECs with an FGFR-1 expression vector, which resulted in over-expression of FGFR-1 protein in approximately 40% of cells. FGF-1 increased promatrilysin expression in FGFR-1-transfected PrECs 4-fold over mock-transfected cells, and this induction was inhibited by a specific FGFR-1 inhibitor, SU5402, and by co-expression of a dominant negative FGFR-1 protein. Our results demonstrate that aberrant FGFR-1 expression, an epigenetic phenomenon that has been associated with prostate cancer progression, allows induction of promatrilysin expression by FGF-1 in PrECs.
- Published
- 2001
- Full Text
- View/download PDF